Lv6
2850 积分 2022-04-01 加入
Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia
5天前
已完结
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
6天前
已完结
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
6天前
已完结
Evaluating the impact of a pharmacist-led venetoclax ramp-up clinic for chronic lymphocytic leukemia patients: A retrospective chart review
8天前
已完结
Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia
11天前
已关闭
Therapeutic advances in chronic lymphocytic leukemia: A focus on molecular pathogenesis, targeted therapies, and supportive care
14天前
已完结
TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?
18天前
已完结
Comparing the Efficacy and Safety of First-Line Treatments for Chronic Lymphocytic Leukemia: A Network Meta-Analysis
27天前
已完结
Deletion of 17p in cancers: Guilt by (p53) association
1个月前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
1个月前
已完结
皖公网安备34019202002308
